Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Latest Information Update: 26 Mar 2025
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Cytarabine/daunorubicin (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Mitoxantrone (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
Most Recent Events
- 24 Mar 2025 Planned primary completion date changed from 31 May 2025 to 30 Jun 2025.
- 24 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 22 Mar 2023 Planned End Date changed from 31 Dec 2026 to 31 Dec 2027.